Ubidecarenone

Company’s presentations highlight the power of mitochondrial medicine and protein homeostasis technologies to address aggressive cancers including glioblastoma and pancreatic cancerBOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company focused on mitochondrial biology and protein homeostasis, today announced the presentation of seven presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30, 2025, in Chicago. The presentations highlight BPGbio’s advances in mitochondrial medicine, immuno-oncology, and precision diagnostics, powered by its proprietary NAi Interrogative Biology® Platform. The featured research spans BPGbio’s oncology pipeline and precision medicine efforts, including mechanistic and clinical insights into BPM31510, a first-in-class oxidized CoQ10 nanodispersion that has demonstrated encouraging results in multiple clinical trials in oncology and other mitochondrial disease areas, and BRG399, a novel microtubule-binding agent that induces immunogenic cell death (ICD). These presentations reinforce BPGbio’s leadership in reprogramming cancer metabolism and targeting mitochondrial dysfunction to drive therapeutic advancement. “We are proud of the tremendous progress across our oncology pipeline at BPGbio both in the BPM31510 and BRG399 franchises. Our NAi platform has revealed hallmark mechanistic insights into mitochondrial control mechanisms in cancer,” said Niven R. Narain, Ph.D., President and CEO at BPGbio. “Our AACR presentations reinforce the importance of stabilizing mitochondrial function and capacity in oncology drug development. BPGbio is now keenly focused on advancing our clinical data and assessing the best commercialization partners to serve patients and families.” Highlights from BPGbio’s AACR 2025 presentations include: Clinical Progress in GBM: A Phase 2 trial of BPM31510 in newly diagnosed glioblastoma multiforme (GBM) demonstrates favorable tolerability and early signals of disease control, reinforcing its potential to address one of oncology’s toughest indications.Mitochondrial Reprogramming in the Tumor Microenvironment: BPM31510 remodels immune landscapes and rewires cancer metabolism, showing immune-enhancing and anti-tumor effects in an immunogenic oncology model.Ferroptosis-Independent Apoptosis: Data show BPM31510 induces ROS-mediated apoptosis in cancer cells without triggering ferroptosis, underscoring a novel mechanism of selective cytotoxicity.C6 Glioma Warburg Reversal: BPM31510 reverses the Warburg effect in quinone-deficient glioma models, restoring oxidative phosphorylation leading to tumor resolution in vivo.BRG399 as a Next-Generation ICD Agent: Preclinical studies show BRG399 drives potent immunogenic cell death and immune infiltration, especially at lower doses, positioning it as a strong candidate for combination immunotherapy.Targeting CoQ Deficiency in Cancer: Multi-omic analysis of TCGA and GTEx datasets identifies cancers with disrupted ubiquinone biosynthesis pathways, spotlighting new indications for mitochondrial-targeted therapies.Project Survival – Early Detection of PDAC: A 7-year, multi-site biomarker study identified a four-protein diagnostic panel that distinguishes pancreatic cancer patients from at risk populations with high sensitivity and specificity. “The breadth of our AACR data—spanning diagnostics, drug mechanism of action, and immuno-oncology— showcases the power of BPGbio’s NAi Interrogative Biology Platform to link biology to therapeutic outcomes,” said Michael Kiebish, Ph.D., Vice President, Platform and Translational Sciences at BPGbio. “This reinforces the critical importance of mitochondrial medicine and protein homeostasis in oncology and immunology to impact preclinical and clinical development leading to improved outcomes for patients.” Presentation Details: Abstract 1591 / 7: Mechanisms of BPM31510-induced cell death in cancer: lipid peroxidation and apoptosis pathwaysPresentation: Monday, April 28, 2025, 9:00 a.m. – 12:00 p.m. in Poster Section 16 Abstract 1527 / 9: Reversal of the Warburg Effect with BPM31510 treatment in a quinone deficient C6 Glioma resulting in efficacyPresentation: Monday, April 28, 2025, 9:00 a.m. – 12:00 p.m. in Poster Section 14 Abstract 3277 / 9: Investigating the link between metabolic reprogramming and immune modulation in tumors: exploring the therapeutic potential of BPM31510Presentation: Monday, April 28, 2025, 2:00 p.m. – 5:00 p.m. in Poster Section 30 Abstract 4177 / 27: Integrated assessment of alterations in coenzyme Q biosynthesis genes impacting cancer metabolism leading to critical vulnerabilities in tumorsPresentation: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. in Poster Section 13 Abstract 5937 / 29: Development of a protein and clinical multiparametric biomarker panel for assessing pancreatic adenocarcinoma riskPresentation: Tuesday, April 29, 2025, 2:00 p.m. – 5:00 p.m. in Poster Section 32 Abstract CT242 / 11: A phase 2 study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapyPresentation: Tuesday, April 29, 2025, 2:00 p.m. – 5:00 p.m. in Poster Section 51 Abstract 6161 / 13: Exploring BRG399, a novel microtubule-binding agent, as an inducer of immunogenic cell death in cancer therapyPresentation: Tuesday, April 29, 2025, 2:00 p.m. – 5:00 p.m. in Poster Section 40 About BPM31510BPM31510IV is BPGbio’s lead candidate in late-stage development for aggressive solid tumors such as glioblastoma multiforme (GBM) and pancreatic cancer. Other topical and oral formulations of the investigational agent are also being developed as a potential treatment for several rare diseases. The compound has demonstrated a tolerable safety profile and shown potential clinical benefits across multiple disease indications. Validated by BPGbio’s NAi Interrogative Biology platform, BPM31510 induces a hallmark shift in the tumor microenvironment (TME) by modulating mitochondrial oxidative phosphorylation in aggressive tumors, leading to cancer cell death. In many mitochondrial diseases, restoring CoQ10 levels can overcome the effect of mutations in genes that lead to mitochondrial dysfunction. BPM31510 has been granted Orphan Drug Designation by the FDA for GBM, pancreatic cancer, and epidermolysis bullosa (EB), as well as Rare Pediatric Disease Designation for primary CoQ10 deficiency and EB. About BRG399BRG399 is a BPGbio-developed candidate being studied for its therapeutic potential as a treatment for solid and liquid tumor cancers as well as diseases associated with inflammation. This experimental drug, a first-in-class, anti-mitotic agent with broad-spectrum anti-cancer activity and favorable pharmacological properties for clinical testing, is being designed for oral delivery. BRG399 is leading the new oncology drug pipeline for BPGbio which includes drug candidates uniquely targeting E2 enzymes. About BPGbioBPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.Media Contact: media@bpgbio.com

在日常生活中，老年人可能会遇到各种各样的健康问题，如头痛、胃痛、失眠、疲劳等。面对这些问题，许多老年人寻求各种方法来改善健康状况。而谷维素，这种几块钱一瓶的“神奇”药物，或许能为老年人带来意想不到的健康益处。谷维素的药理作用，不可不知谷维素是从米糠中提取的天然混合物，所以又称“米糠素”，是以三萜醇（烯）为主体的阿魏酸酯混合物。其具有两大功能：1、自主调节神经功能：谷维素能减少分泌平衡障碍，改善精神心理失调症状，稳定情绪、减轻焦虑及紧张状态，可以改善睡眠。2、调节间脑功能：谷维素激活与自主神经相关的下丘脑及大脑边缘系统。现代人饮食精细，吃的都是精制大米、精白面粉等“细粮”。在精加工的过程中，谷皮、糊粉层和胚芽被去除，导致谷维素、膳食纤维及B族维生素等天然营养素大量流失。除了糙米、全麦、玉米、青稞、高粱等全谷物，芸豆、绿豆等杂豆类、山药、芋头等块茎类，都属于粗粮。日常可以多吃一些。《中国居民膳食指南》推荐：健康成年人每天应摄入谷类食物200~300g。其中全谷物和杂豆类50~150g； 薯类50~100g。如果你有以下五种情况之一，可能意味着「植物神经功能紊乱」，需要额外补充谷维素了。谷维素：五类疾病常用谷维素主要作用于间脑的植物神经系统与分泌中枢，从而改善和调节植物神经功能失调、内分泌平衡障碍及精神失调等症状。1、焦虑、失眠老年人常常面临失眠的问题，这可能与植物神经功能紊乱有关。谷维素能够调节自主神经系统，减少内分泌平衡障碍，从而改善精神神经失调症状。对于轻中度的失眠，谷维素具有很好的疗效，尤其对中老年人因植物神经功能紊乱所引起的失眠具有明显效果。老年人可以在医生指导下，将谷维素与维生素B1或安神补脑液搭配使用，以改善睡眠质量。2、胃肠神经官能症如果你情绪紧张时容易腹痛、腹胀，或腹泻、便秘交替出现，伴随食欲减退、餐后饱胀感，做了胃肠检查却显示一切正常。可能是胃肠神经官能症。除了应用谷维素之外，还可以辨证搭配香砂养胃丸、参苓白术丸、保和丸等中成药以增强疗效。3、心脏神经官能症出现心悸、胸闷、心前区短暂刺痛或隐痛，伴有焦虑、多汗、乏力，但是心电图、冠脉CT、心脏彩超等专业心脏检查显示无器质性异常时，多考虑心脏神经官能症。也可以通过补充谷维素来缓解症状。辨证搭配生脉饮、稳心颗粒、参松养心胶囊等中成药效果更佳。4、经前期综合征有些女性的朋友在来月经之前会出现烦躁、焦虑、乳房胀痛、头痛、恶心呕吐、食欲不振、水肿等表现。这类症状统称为“经前期综合征”。补充一点谷维素也能缓解。辨证搭配乌鸡白凤丸、柴胡疏肝丸、逍遥丸等中成药效果更佳。5、更年期综合征一到更年期，特别容易出现焦虑、急躁、易怒、心悸失眠、潮热盗汗等一系列症状。此时也可以尝试补充谷维素。同时，还可辨证应用坤泰胶囊、更年安颗粒、坤宝丸、灵莲花颗粒等中成药。此外，不少现代研究证明，谷维素还有辅助降血脂、减轻心绞痛、治疗多发性口腔溃疡、治疗小儿异食癖等多种作用。谷维素的用药禁忌，不可不记1、特殊人群不宜服用：胃及十二指肠溃疡者，不宜服用谷维素。2、可能出现不良反应：服用谷维素后，偶有患者出现胃部不适、恶心、呕吐、口干、疲乏、皮疹、乳房胀痛、油脂分泌过多、脱发、体重增加等不良反应，停药后症状可消失。3、注意服用体位：不可躺着服用谷维素，因谷维素容易黏附食道，刺激食道壁。服药期间，不要进食辛辣刺激食物。服用谷维素有讲究谷维素作为一种天然提取物，其安全性已获广泛认可。说明书推荐谷维素日剂量为10mg~60mg，满足日常养护需求。但研究显示，为获更显著益处，可能需更大剂量。针对老年人，结合个人状况及专业评估，剂量可调整至300mg~600mg。为减少副作用风险，建议分次服用，并密切关注大剂量用药的副作用及实际效益。谷维素建议饭后服用，以促进吸收并减少胃肠刺激。与维生素E、辅酶Q10等亲脂性抗氧化剂联合使用，可发挥协同作用，增强效果。谷维素以其多样的生物活性，在老年健康管理中展现巨大潜力，合理补充有助于缓解慢性疾病症状，延缓衰老，提升生活质量。未来，谷维素在老年健康领域的应用前景将更加广阔。来源丨医护多药学学霸综合整理 喜欢我们文章的朋友点个“在看”和“赞”吧，不然微信推送规则改变，有可能每天都会错过我们哦~免责声明“汇聚南药”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请在留言栏及时告知，我们会在24小时内删除相关信息。信息来源：医护多药学学霸往期推荐本平台不对转载文章的观点负责，文章所包含内容的准确性、可靠性或完整性提供任何明示暗示的保证。